Appropriateness of Methodist Health System(MHS) Inter-facility Transfers of Traumatic Intracranial Subarachnoid Hemorrhage and Spontaneous Bleeds for Level-1 Advanced Surgical Intervention
Launched by METHODIST HEALTH SYSTEM · Nov 15, 2023
Trial Information
Current as of September 07, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well patients with serious brain injuries, specifically traumatic intracranial subarachnoid hemorrhage (a type of bleeding in the brain), are transferred between different hospitals for advanced surgical care. The goal is to understand if these transfers from Methodist Mansfield Medical Center or Methodist Charlton Medical Center to Methodist Dallas Medical Center are appropriate and effective for patients needing urgent treatment.
To participate in this study, individuals must be at least 18 years old and have a diagnosis of traumatic intracranial subarachnoid hemorrhage or spontaneous bleeding in the brain. If you or a loved one are hospitalized at one of the participating centers and are transferred for treatment, you may be eligible to join the trial. Participants will help researchers gather important information on the treatment process and outcomes, which can ultimately improve care for future patients facing similar issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥18 years old
- • Diagnosed with traumatic intracranial subarachnoid hemorrhage or a spontaneous bleed
- • Patients originating at Methodist Mansfield medical center (MMMC) or Methodist Charlton medical center(MCMC)and subsequently transferred to Methodist Dallas medical center (MDMC)
- Exclusion Criteria:
- • Does not meet inclusion criteria defined in section 3.1
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Richard Meyrat, MD
Principal Investigator
The Methodist Hospital Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported